Transgene SA
TRGNF
$0.85
-$0.15-15.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -91.41% | -96.01% | -98.78% | -98.98% | -26.50% |
| Total Other Revenue | 15.84% | 27.52% | 43.02% | 13.68% | -5.86% |
| Total Revenue | 17.53% | 16.92% | 17.46% | -4.49% | -19.54% |
| Cost of Revenue | 3.10% | 12.72% | 25.60% | 19.10% | 15.90% |
| Gross Profit | 0.18% | -11.66% | -27.91% | -26.72% | -28.81% |
| SG&A Expenses | -1.69% | -9.11% | -15.23% | -4.54% | 11.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 3,832.73% | 1,325.05% | 164.17% | -98.80% | -102.30% |
| Total Operating Expenses | 5.03% | 9.96% | 16.95% | 12.34% | 10.85% |
| Operating Income | -2.80% | -8.62% | -16.85% | -16.30% | -18.85% |
| Income Before Tax | -15.28% | -32.98% | -61.58% | -54.55% | -52.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.28% | -32.98% | -61.58% | -54.55% | -52.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.28% | -32.98% | -61.58% | -54.55% | -52.26% |
| EBIT | -2.80% | -8.62% | -16.85% | -16.30% | -18.85% |
| EBITDA | -2.60% | -8.91% | -17.79% | -17.76% | -20.91% |
| EPS Basic | 7.64% | -5.12% | -23.30% | -26.08% | -32.74% |
| Normalized Basic EPS | 7.66% | -5.14% | -23.54% | -26.28% | -32.96% |
| EPS Diluted | 6.60% | -6.80% | -25.91% | -27.47% | -32.96% |
| Normalized Diluted EPS | 7.66% | -5.14% | -23.54% | -26.28% | -32.96% |
| Average Basic Shares Outstanding | 23.88% | 27.15% | 30.91% | 23.47% | 15.98% |
| Average Diluted Shares Outstanding | 23.88% | 27.15% | 30.91% | 23.47% | 15.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |